AstraZeneca Enters Deal to Acquire Cell Therapy Firm EsoBiotec for Up to $1 Billion

, MT Newswires -  3:53 AM ET 3/17/2025 Company News

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

03:53 AM EDT, 03/17/2025 (MT Newswires) -- AstraZeneca ( AZN ) has agreed to acquire EsoBiotec for a total consideration of up to $1 billion, EsoBiotec said Monday.

The consideration consists of an initial payment of $425 million, and up to $575 million in contingency payments.

The deal includes EsoBiotec's Engineered NanoBody Lentiviral delivery platform which has potential application in cancer therapy, the biotechnology company said.

Closing of the deal is expected to occur in Q2, subject to customary closing conditions.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.